Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,689 recruiting studies in this area right now.
By phase
- Not applicable9,836
- Phase 24,475
- Phase 12,738
- Phase 1/Phase 21,689
- Phase 31,406
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,231
- Prostate Cancer659
- Cancer658
- Colorectal Cancer495
- Lung Cancer430
- Ovarian Cancer338
- Multiple Myeloma330
- Gastric Cancer300
- Pancreatic Cancer298
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma286
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors196
- Esophageal Cancer195
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University312
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic236
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto126
Where studies are running
- California1,427
- Texas642
- Arizona513
- Florida443
- Alabama421
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania240
Recruiting studies20,689 total
- NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Miami, FloridaAges 18 years+ - NCT05800340RecruitingPhase 2
Immunotherapy before surgery for certain rare lung cancer mutations
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
Guanzhou, GuangdongAges 18 years+ - NCT05800405RecruitingEarly Phase 1
Radiation before CAR T therapy for large B-cell lymphoma
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Duarte, CaliforniaAges 18 years+ - NCT05800587RecruitingPhase 2
Reduced-dose chemotherapy for advanced lung cancer
This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05800574RecruitingPhase 2
Targeted neck radiation for p16-positive favorable throat cancer
This Phase 2 study tests whether a more precisely targeted radiation plan to the neck can work for people with p16-positive oropharynx cancer that is considered “favorable risk.” Doctors use special imaging to map where lymph nodes are likely involved, aiming to treat the right areas while avoiding unnecessary treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05800535Recruiting
Screening for muscle loss and thinking changes after cancer
This study looks at how common muscle weakness (sarcopenia) and thinking or memory changes (often called “chemobrain”) are in people after cancer treatment. It may help teams understand what support could be most helpful after chemotherapy.
Pierre-BéniteAges 18–74 - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05802069Recruiting
Personalized cancer treatment based on your medical profile
This trial is studying a way to help guide individualized cancer treatment using your existing medical information. If you receive cancer care at the specific study sites, you may be able to enroll.
Milwaukee, WisconsinAges 18 years+ - NCT05802121RecruitingEarly Phase 1
Testing a gut bacteria supplement side effects during prostate hormone therapy
This early-phase study looks at how changing gut bacteria (especially Akkermansia) affects metabolic side effects in men starting prostate hormone therapy (ADT). It may help researchers understand how to reduce or manage side effects for people on ADT.
London, OntarioAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05802407Recruiting
ctDNA blood test monitoring after pancreatic cancer surgery
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
BeijingAges 18 years+ - NCT05802394Recruiting
Using blood tests to track cancer after pancreatic treatment
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
BeijingAges 18 years+ - NCT05803018RecruitingPhase 1/Phase 2
Study drug for advanced gynecologic cancer that stopped working
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05803928RecruitingPhase 1
Ablation plus lenvatinib and anti-PD-1 to prevent liver cancer return
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
Guangzhou, GuangdongAges 18–75 - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Irvine, CaliforniaAges 18 years+ - NCT05803941RecruitingPhase 4
Study long-term safety of a prostate cancer drug
This trial checks the long-term safety (how it affects you over time) of lutetium-177 vipivotide tetraxetan in people with prostate cancer. You may be eligible if you already received the related drug in a prior Novartis prostate cancer study and can complete the required follow-up tests.
Scottsdale, ArizonaAges 18–100 - NCT05804331Recruiting
Endoscopy treatment study for large upper stomach/throat lesions
This trial studies a specialized endoscopy procedure to remove larger abnormal growths in the upper digestive tract. It may help people whose lesion size and depth make certain removal techniques a better fit.
Sydney, New South WalesAges 18 years+ - NCT05804227RecruitingEarly Phase 1
Ulixertinib for glioma driven by MAPK pathway
This early-phase trial tests ulixertinib (a targeted pill) to see how well it works for certain gliomas driven by the MAPK/RAF-MEK-ERK signaling pathway. It also looks at whether the drug can help control tumor growth around the time of treatment planning.
Houston, TexasAges 18 years+ - NCT05804578Recruiting
Blood test monitoring for metastatic breast cancer treatment
This trial studies using a blood test to monitor how treatment is working in people with metastatic breast cancer. It may help your care team track your cancer over time with a simpler test.
Kingston, OntarioAges 18 years+ - NCT05805319Recruiting
Food intervention for people with lung cancer on immunotherapy
This trial studies whether a specific diet can help people with non-small cell lung cancer who are receiving immunotherapy (a standard cancer treatment). It mainly checks whether participants can follow the diet plan and tolerate the food changes safely.
Montreal, QuebecAges 18 years+ - NCT05804916RecruitingPhase 2/Phase 3
Tracking-guided radiation for left breast after surgery
This trial tests a radiation planning and monitoring approach that uses surface tracking and breathing control to deliver large-area radiation more accurately for left breast cancer. It may help improve how consistently treatment is delivered while accounting for chest movement.
Beijing, Beijing MunicipalityAges 18–70 - NCT05804786Recruiting
Study of bronchoscopy to diagnose lung spots
This study follows people who have lung “spots” that look like possible lung cancer and need a biopsy to figure out what they are. It uses a guided breathing-tube procedure to safely collect tissue so doctors can make a diagnosis.
DaeguAges 19 years+ - NCT05805098RecruitingPhase 2/Phase 3
Testing Venetoclax with chemo for newly diagnosed AML
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
Suzhou, JiangsuAges 18–60
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,689 recruiting oncology studies from the U.S. registry right now, out of 31,955 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.